Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SHIGETECVAX

Financiado

Cerrado

Early clinical development of a live attenuated combination vaccine against Shi...

Early clinical development of a live attenuated combination vaccine against Shigella and ETEC diarrhoea Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of cu... ver más

28/02/2025

EUROPEAN VACCINE I...

9M€

Presupuesto del proyecto: 9M€

Líder del proyecto

EUROPEAN VACCINE INITIATIVE E.V No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-04-30

SC1-BHC-15-2018: New anti-infective agents for preve...

I+D

Cerrada hace 7 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

EUROPEAN VACCINE INITIATIVE...

359.76K€ | Lider

EVQ

5.02M€ | Participante

INTERNATIONAL CENTRE FOR DIA...

UGOT - GOETEBORGS UNIVERSITE...

749.84K€ | Participante

Proyectos interesantes

STOPENTERICS

Medical Technol...

Data Science

16M€ Cerrado

RTI2018-097625-B-I00

Medical Technol...

Biotechnology

290K€ Cerrado

AGL2010-17394

Medical Technol...

Vaccinology

126K€ Cerrado

BFU2009-07206

Medical Technol...

Pharmaceutical...

237K€ Cerrado

ImmunoFarm

Medical Technol...

Biotechnology

161K€ Cerrado

ETVAX

Medical Technol...

Vaccinology

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 69 meses Fecha Inicio: 2019-04-30
Fecha Fin: 2025-02-28

Líder del proyecto

EUROPEAN VACCINE INITIATIVE E.V No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 9M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores